共 36 条
[1]
Steen V.D.(1994)Severe restrictive lung disease in systemic sclerosis Arthritis Rheum 37 1283-1289
[2]
Conte C.(2002)Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome Am J Respir Crit Care Med 165 1581-1586
[3]
Owens G.R.(1992)High resolution computed tomography as a predictor of lung histology in systemic sclerosis Thorax 47 738-742
[4]
Medsger T.A.(2006)Cyclophosphmide versus placebo in scleroderma lung disease N Engl J Med 354 2655-2666
[5]
Bouros D.(1993)Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil Immunol Rev 136 5-28
[6]
Wells A.U.(2000)Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group N Engl J Med 343 1156-1162
[7]
Nicholson A.G.(1999)Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement J Am Soc Nephrol 10 1965-1971
[8]
Wells A.U.(2002)Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome Muscle Nerve 25 286-288
[9]
Hansell D.M.(2001)Mycophenolate mofetil for dermatomyositis Dermatology 202 341-343
[10]
Corrin B.(2006)Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease Chest 130 30-36